Harnessing the therapeutic power of mitochondria
Minovia Therapeutics is the first clinical stage company to use mitochondrial transplantation approach with the hope to bring life changing therapies to people suffering from mitochondrial dysfunction.
From rare diseases to aging, Minovia is pioneering mitochondria-based therapies – a science-backed platform for healthier life.
Mitochondria
Mitochondria are unique organelles producing most of the cells’ energy demands and perform multiple crucial functions, impacting cell biology and health
Mitochondrial Diseases
A heterogeneous group of disorders that affects children or adults, caused by mutations or deletions in nuclear or mitochondrial DNA (mtDNA) that lead to mitochondrial dysfunction, displaying multi-organ failure.
Mitochondrial Augmentation
Mitochondrial Augmentation Technology (MAT) is an investigational platform targeting the root-cause of mitochondrial diseases, as rare or common as they may be
“After years of mitochondrial research my journey with Minovia began with a profound question: If we could harness the incredible power of mitochondria for therapeutic purposes, how many lives could be transformed?”
Natalie Yivgi-Ohana, PhD
Founder and CEO
Read More
Mitochondrial Augmentation Technology (MAT) platform includes transplantation of healthy, functional mitochondria in mitochondrial disease patients and proprietary analytical assays and biomarkers intended to measure mitochondrial health.
Our collective Responsibility
Collaborations
Developing transformative therapies to patients requires collaborative spirit and joint efforts from many parties. We believe in cross-discipline collaboration and partner with others who share our commitment and purpose.
Patients
We value our partnerships with Patients’ Advocacy Groups. Their insights and collaboration ensure that the voices of mitochondrial disease patients are heard and applied to our development plans and inspire our devotion.
Leadership
Bringing together our expertise in science, technology, analytical development, regulatory and manufacturing to accelerate the collective understanding of mitochondrial dysfunction and deliver therapy that is meaningful to patients.